Catalyst OrthoScience marked more than 10,000 total shoulder arthroplasty procedures and closed $20 million in equity and venture debt financing.
The company is set up for the next stage of commercial adoption, with funding to support expansion of its distribution channel, further investment in talent and training and launch of new products.
“Catalyst has made significant progress since its first case in 2016,” said Carl O’Connell, CEO of Catalyst. “Our unique ability to blend true innovation with unmatched efficiency and predictable outcomes is transforming an industry that has long been burdened by solutions that introduce inefficiencies and inflate procedural costs without also delivering improved patient outcomes. At Catalyst, we’re closing those gaps with our single-tray systems, proprietary instrumentation, fewer surgical steps, and purposefully designed implants. This is increasingly important as procedures shift to ambulatory surgery centers (ASC) where there is a growing desirability for solutions that reduce case turnaround times and sterilization costs, limit storage space needs, and ease the workload on the surgical team.”
Catalyst OrthoScience marked more than 10,000 total shoulder arthroplasty procedures and closed $20 million in equity and venture debt financing.
The company is set up for the next stage of commercial adoption, with funding to support expansion of its distribution channel, further investment in talent and training and launch of new...
Catalyst OrthoScience marked more than 10,000 total shoulder arthroplasty procedures and closed $20 million in equity and venture debt financing.
The company is set up for the next stage of commercial adoption, with funding to support expansion of its distribution channel, further investment in talent and training and launch of new products.
“Catalyst has made significant progress since its first case in 2016,” said Carl O’Connell, CEO of Catalyst. “Our unique ability to blend true innovation with unmatched efficiency and predictable outcomes is transforming an industry that has long been burdened by solutions that introduce inefficiencies and inflate procedural costs without also delivering improved patient outcomes. At Catalyst, we’re closing those gaps with our single-tray systems, proprietary instrumentation, fewer surgical steps, and purposefully designed implants. This is increasingly important as procedures shift to ambulatory surgery centers (ASC) where there is a growing desirability for solutions that reduce case turnaround times and sterilization costs, limit storage space needs, and ease the workload on the surgical team.”
Copy to clipboard 
